Recipharm
Dr. Hans Lennernäs pictured left.Recipharm Pharmaceutical Development has appointed Dr. Hans Lennernäs to its Operating Board. Dr. Lennernäs is a Professor of Biopharmaceutics at Uppsala University, Sweden. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery, controlling a budget of €24.5 million. His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.
Dr. Lennernäs has served as the Principal Investigator in an extensive collaboration with the FDA, University of Michigan, US, and Medical Product Agency, Sweden, over the course of several years, in which he developed a new guideline for the Biopharmaceutics Classification System. He has established an extensive and widely used human permeability database.
In addition to his academic achievements, Dr. Lennernäs has built an entrepreneurial reputation by cofounding several companies, including DuoCort Pharma AB, and LIDDS AB, whilst investing in a number of patents.
“I am very much looking forward to serving on the Board of Directors at Recipharm Pharmaceutical Development,” commented Lennernäs. “Indeed, this is a company with an excellent track record and an impressive long-term strategy in place.”
“We are very pleased to welcome a Board Member of Hans Lennernäs’s calibre,” remarked General Manager Maria Lundberg. “His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition. I look forward to Recipharm benefiting from his contribution and insights that will help the company perpetuate its track record of commercial success."
Recipharm AB, +46 8 602 52 00, info@recipharm.com, www.recipharm.com.